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Medication-overuse headache (MOH) is a secondary
chronic headache developing as a consequence of pro-
longed overuse of symptomatic headache drugs for at
least 3 consecutive months. It usually, but not invariably,
resolves after the overuse is discontinued [1]. Benefit of
acute withdrawal of the overused medication has been
shown to be effective [2]; performing a transitional ther-
apy (“bridge therapy”) during the days of withdrawal
may ensure symptomatic relief from rebound headache
and avoid withdrawal symptoms. In this setting, i.v.
methylprednisolone may have a protective role [3].
This retrospective study aimed to evaluate the effec-
tiveness of detoxification protocol applied in our Head-
ache Centre, which consists in interruption of the
abused drug and in the intravenous administration of
methylprednisolone 125 mg plus diazepam 10 mg and
esomeprazole 40 mg for 5 consecutive days. Depending
on patients’ features, prophylactic therapy for chronic
headache was either introduced or modified by the end
of the wash-out. We enrolled 36 patients with MOH
who underwent wash-out between 2010 and 2014, for
whom follow-up data were available. Then we compared
these patients with a control group of 21 MOH patients
who did not undergo detoxification protocol, but only
changed prophylactic therapy. Considered end points
were mean monthly days of headache and the percen-
tage of response to treatment at one (T1) and three
months (T3): patients were divided into “responders”
and “high responders” if reduction was > 50%.
At T0, mean monthly days of headache was 25 in the
washout group and 20 in the control group; at T1 means
decreased to 8 in the washout group and 11 in the con-
trol group (Mann-Whitney U test, p 0.012), with a 68%
reduction in the washout group and 40% reduction in the
control group. At T3 means were 10 for both groups (p
0.103), with a reduction from baseline of 60% in the
washout group and 50% in the control group. At T1 we
found 54.4% of “responders” in the washout group, versus
22.8% of responders in the control group (Fisher’s exact
test, p 0.04); “high responders” rates were 40.4% in the
washout group versus 8.8% in the control group
(p 0.004). At T3 differences in “responders” and “high
responders” rate between the two groups were attenu-
ated, losing statistical significance.
This retrospective study shows that a detoxification
protocol with i.v. methylprednisolone and diazepam is
widely effective and ensures an adequate reduction of
headaches.
Written informed consent to publication was obtained
from the patient(s).
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